<DOC>
	<DOCNO>NCT00003234</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness vinorelbine treat child recurrent refractory cancer .</brief_summary>
	<brief_title>Vinorelbine Treating Children With Recurrent Refractory Cancers</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate child recurrent refractory malignancy treat vinorelbine . II . Assess toxic effect drug child . OUTLINE : Patients receive vinorelbine IV 6-10 minute weekly week 1-6 . Treatment repeat every 8 week total 10 course absence disease progression unacceptable toxicity . Patients follow every 4 month 2 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A maximum 100 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent refractory solid malignant tumor childhood include : Soft tissue sarcoma Rhabdomyosarcoma Nonrhabdomyosarcoma Extraosseous Ewing 's sarcoma CNS tumor Astrocytoma Primitive neuroectodermal tumor Atypical teratoid/rhabdoid tumor Ependymoma Recurrent neuroblastoma Measurable disease No 2 prior treatment regimens PATIENT CHARACTERISTICS : Age : 21 diagnosis Performance status : ECOG 02 Life expectancy : At least 2 month Hematopoietic : For patient solid tumor ( unless marrow involvement ) : Absolute neutrophil count ( ANC ) least 1000/mm3 Platelet count least 100,000/mm3 ( transfusion independent ) Hemoglobin least 10 g/dL ( RBC transfusion allow ) For patient post bone marrow transplantation : ANC least 1,000/mm3 Platelet count least 50,000/mm3 ( transfusion independent ) Hemoglobin least 10 g/dL ( RBC transfusion allow ) Hepatic : Total bilirubin great 1.5 time normal SGOT/SGPT le 2.5 time normal Renal : Creatinine great 1.5 time normal OR Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Neurologic : Seizure disorder allow well control CNS toxicity great grade 2 PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 month since prior bone marrow transplantation No concurrent immunomodulating agent Chemotherapy : At least 2 week since prior chemotherapy ( 4 week nitrosourea ) recover No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroids except increase intracranial pressure due CNS tumor Radiotherapy : At least 6 month since prior radiotherapy craniospinal axis , spine , and/or 50 % bony pelvis Concurrent radiotherapy localize painful lesion allow least one measurable lesion radiation field Surgery : Not specify Other : No concurrent participation another CCG , POG , COG therapeutic study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
</DOC>